Agenus genital herpes vaccine succeeds in mid-stage trial

(Reuters) – Agenus Inc said a mid-stage trial of its experimental genital herpes vaccine reduced the rate at which patients’ were shedding the virus. The 15 percent reduction in viral shedding in patients receiving the vaccine compared to those on a placebo, who showed no reduction.
Sexual Health News Headlines – Yahoo! News